IP Library Granted Patent US 8,367,827
Granted Patent B2
US 8,367,827 · App. 12/627,355 · Granted Feb 5, 2013

Process for preparing hydrocodone using a super acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,827
App. No.
12/627,355
Granted
Feb 5, 2013
Kind
B2
Abstract

The present disclosure generally relates to a process for converting a fused, tricyclic compound to a fused, tetracyclic compound that includes a furan ring therein. More particularly, the present disclosure related to a process for preparing a hydrocodone compound, or a compound structurally related thereto, and in particular (+)-hydrocodone, by subjecting a structurally corresponding sinomenine starting compound to a super acid-assisted furan ring closure reaction.

Claims (38)

1. A process for carrying out a furan ring closure reaction to transform a compound of Formula (III) to a compound of Formula (IV):

wherein:

R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, cyano, hydrocarbyl, substituted hydrocarbyl and NR c R d , where each of R c and R d are independently selected from the group consisting of hydrogen, hydroxy and hydrocarbyl;

R 3 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 4 is selected from the group consisting of hydrogen, acyl, trialkylsilyl, tertiary-alkyl, aryl-substituted methyl, and alkoxy-carbonyl;

R 6 is a substituent at C5 or C7 and is selected from hydrogen, alkyl, and acyl; and, the dashed bond between carbon atoms C7 and C8 indicates the optional presence of a carbon-carbon double bond;

the process comprising contacting the compound of formula (III) with a super acid under process conditions suitable for forming a bond between the oxygen atom of the —OR 4 substituent and the C5 carbon atom to form a furan ring.

2. The process of claim 1 , wherein the super acid is selected from the group consisting of CF 3 SO 3 H (trifluoromethanesulfonic acid), HBF 4 (tetrafluoroboric acid), HPF 6 (fluorophosphoric acid), FSO 3 H (fluorosulfuric acid), HSbF 6 (fluoroantimonic acid), FP(O)(OH) 2 (fluorophosphoric acid), and combinations thereof.

3. The process of claim 1 , wherein the super acid and the compound of Formula (III) are contacted in a reaction mixture further comprising an aprotic solvent.

4. The process of claim 3 , wherein the aprotic solvent is selected from the group consisting of chloroform, dichloromethane, chlorobenzene, toluene, dichloroethane, tetrahydrofuran, diethyl ether, acetonitrile, and combinations thereof.

5. The process of claim 1 , wherein the super acid is formed in situ.

6. The process of claim 5 , wherein the super acid is formed in situ by reacting water or methanol with an anhydride of the super acid.

7. The process of claim 1 , wherein the process further comprises contacting the compound of Formula (III) with an acid that is not a super acid.

8. The process of claim 7 , wherein the acid that is not a super acid is selected from the group consisting of MeSO 3 H, CH 3 C 6 H 4 SO 3 H, H 3 PO 4 and CF 3 CO 2 H, and combinations thereof.

9. The process of claim 1 , wherein R 1 , R 2 and R 4 are hydrogen.

10. The process of claim 9 , wherein R 3 and R 5 are methyl.

11. The process of claim 1 , wherein R 3 and R 5 are hydrogen.

12. The process of claim 1 , wherein R 3 is methyl and R 5 is hydrogen.

13. The process of claim 1 , wherein R 1 and R 4 are hydrogen; R 2 is bromine; and R 3 , R 5 and R 6 are methyl.

14. The process of claim 1 , wherein R 1 , R 2 and R 4 are hydrogen; R 3 and R 6 are methyl; and R 5 is cyclopropylmethyl.

15. The process of claim 1 , wherein R 1 , R 2 , R 4 and R 5 are hydrogen and R 3 and R 6 are methyl.

16. The process of claim 1 , wherein R 1 , R 2 , R 3 , R 4 and R 6 are hydrogen; and R 5 is methyl.

17. The process of claim 1 , wherein R 1 , R 2 and R 4 are hydrogen and R 3 , R 5 and R 6 are methyl.

18. The process of claim 17 , wherein the compound of Formula (III) is (+)-hydrocodone.

19. The process of claim 1 , wherein the resulting mixture of the compound of Formula (III) and the super acid is agitated for between about 2 and about 8 hours, or between about 4 and about 6 hours.

20. The process of claim 1 , wherein the resulting mixture of the compound of Formula (III) and the super acid is maintained at a temperature between about −20° C. and about 100° C., or between about 0° C. and about 45° C.

21. The process of claim 1 , wherein the compound of Formula III and the compound of Formula IV have the following structures:

wherein R 6 is H or CH 3 .

22. The process of claim 1 , wherein the compound of Formula III and the compound of Formula IV have the following structures:

wherein R 6 is H or CH 3 .

23. A process for making a compound of Formula (VI):

wherein:

R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, alkoxy, cyano, hydrocarbyl, substituted hydrocarbyl and NR c R d , wherein each of R c and R d are independently selected from the group consisting of hydrogen hydroxy and hydrocarbyl;

R 3 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 4 is selected from the group consisting of hydrogen, acyl, trialkylsilyl, tertiary-alkyl, aryl-substituted methyl and alkoxy carbonyl; and,

R 6 is a substituent at C5 or C7 and is selected from H or CH 3 ;

the process comprising contacting a compound of Formula (V) with a super acid under process conditions suitable for forming a bond between the oxygen atom of the —OR 4 substituent and the C5 carbon atom to form a furan ring.

24. The process of claim 23 , wherein R 1 , R 2 and R 4 are H, and R 3 and R 5 are CH 3 .

Assignments (1)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →